Clinical safety study of temozolomide combined with radiotherapy after glioma resection

The aims of this study were to investigate the efficacy and safety of radiotherapy combined with temozolomide (TMZ) after glioma resection. A total of 86 patients with glioma were randomly divided into two groups (n=43). Group A was treated with 3D conformal radiotherapy combined with TMZ (RTMZ), and Group B was only treated with 3D conformal radiotherapy. The clinical efficacy, postoperative 1, 2 and 3-year survival rate, Karnofsky score, and side effects were compared and analysed. The objective response rate (ORR) and disease control rate (DCR) values in group A were 76.7% and 90.7% respectively, significantly higher than group B (55.8% and 74.4%, P<0.05). The Karnofsky scores of both groups were improved after treatment than before (P<0.05). The median survival period and postoperative 1, 2 and 3-year survival rates in group A were significantly higher than group B (P<0.05). There was no significant difference in the side effects between the two groups (P>0.05). R-TMZ is a safe and effective adjuvant therapy after glioma resection, which can improve short-term and long-term survival rate while not increase side effects